We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Combined Serology and Genotyping Reduces False Positive Diagnosis of Celiac Disease

By LabMedica International staff writers
Posted on 09 Sep 2013
A new diagnostic approach for detection of celiac disease (CD) that combines genomic assessment and serology revealed that this immune disorder is far more common in the Australian population than previously thought but was often diagnosed incorrectly.

Investigators at the Walter and Eliza Hall Institute (Victoria, Australia) and their colleagues combined traditional antibody testing for CD (measuring the immune response to gluten) with an assessment of specific genetic risk markers.

They evaluated serum samples from 356 patients with biopsy-confirmed CD, and from two age-stratified, randomly selected community cohorts of 1,390 women and 1,158 men. More...
The samples were tested for antigluten antibodies by standard serological techniques and (HLA)-DQ genotyping was performed using Taqman SNP genotyping methods (Applied Biosystems, Foster City, CA, USA) following the manufacturer’s protocols.

Results revealed that celiac disease potentially affected at least one in 60 Australian women and one in 80 men. Previous estimates had suggested that the number of Australians with celiac disease was no more than 1%. Furthermore, serogenetic data indicated that testing screen positives for HLA-DQ, or carrying out HLA-DQ and further serology, could have reduced unnecessary gastroscopies due to false-positive serology by at least 40% and by over 70%, respectively.

“Currently, bowel biopsies are recommended for anybody with positive antibody tests,” said contributing author Dr. Jason Tye-Din, a gastroenterologist at the Walter and Eliza Hall Institute. “In this study, the inclusion of a simple genetic test helped identify a substantial number of people whose antibody tests were falsely positive and who did not actually require a bowel biopsy to test for the possibility of celiac disease.”

“It is concerning that a significant number of people in the community with celiac disease have not been diagnosed,” said Dr. Tye-Din. “Accurate and timely diagnosis is important for the health of patients with celiac disease. Making a diagnosis based on a blood test alone or commencing a gluten-free diet without a confirmatory bowel biopsy is inappropriate and can impose an unnecessary and lifelong treatment. Although small bowel biopsy is needed to confirm celiac disease, it is costly and invasive. Reducing unnecessary procedures is better for patients, eliminating an invasive test, and better for the economy by reducing healthcare costs. This study provides a strategy to improve the diagnosis of celiac disease in the community by combining the benefits of antibody and genetic testing.”

Related Links:
Applied Biosystems
Walter and Eliza Hall Institute



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Creatine Kinase-MB Assay
CK-MB Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.